A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms appeared, blood samples showed. A distinct set of autoantibodies emerged ...

which is a humanized IgG4κ antibody raised against α4-integrin (CD49d) was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 2006. Natalizumab is thought to act ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident in the current ...

Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment ...

anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab.

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and ...

which is a humanized IgG4κ antibody raised against α4-integrin (CD49d) was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 2006. Natalizumab is thought to act ...